HC News

• Herpes Zóster
• Helicobacter pylori infection
• The Mediterranean Diet in the prevention and management of cancer
• Dr Cristina Nuño Rodríguez is a specialist in Radiation Oncology at HC Cancer Center
• HC Marbella’s Nuclear Medicine Unit has been accredited as a centre of excellence for PET-CT.
• HC Marbella, the first hospital in Andalusia to acquire the CORI robot for knee joint replacement
• El Dr. Hernández Rubiño participa en el Libro Blanco de la SEORL-CCC con un capítulo dedicado a la Resonancia Magnética en el Diagnóstico de la Patología del Oído Medio
• La Dra. Casilda Llácer Pérez se incorpora a HC Cancer Center como especialista en oncología médica, tumores digestivos y genitourinarios
• Remar para dejar atrás el cáncer de mama
• Obesity is a chronic, non-transmissible, multifactorial condition
• More news

Our colon cancer patients are treated using immunotherapeutic drugs with promising results

Recently, the American Congress of Oncology (#ASCO18) was held in Chicago where the latest advances in #coloncancer , research, through #immunotherapy were presented. Various studies have been carried out on different immunotherapeutic drugs that have given very promising results.

There are currently two immunotherapeutic drugs (Pembrolizumab y Nivolumab) approved for colon cancer caused by a genetic mutation called Microsatellite instability; that cause a deficiency in the DNA repairing mechanisms and therefore there are a greater number of mutations. Although this mutation is not very common (15% of the total number of cases and 4% of the patients in advanced stages) it is important to carry out a study in all patients, given that the subgroup may benefit from such an effective treatment.

In the Oncology Unit at HC Marbella we are already using immunotherapeutic drugs to treat out patients with very good results.

June 5, 2018